Up­dat­ed: FDA adds warn­ing of 'larg­er ar­eas of bleed­ing' in brain to Bio­gen's Aduhelm la­bel

The FDA last week signed off on a safe­ty-re­lat­ed change to the la­bel of Bio­gen’s con­tro­ver­sial Alzheimer’s drug Aduhelm, which has bare­ly mus­tered any sales since its ap­proval be­cause pay­ers have re­fused to cov­er it.

The new la­bel makes clear that physi­cians should, “In­form pa­tients that events of in­trac­ere­bral he­m­or­rhage greater than 1 cm in di­am­e­ter have been re­port­ed in­fre­quent­ly in pa­tients tak­ing ADUHELM, and that the use of an­tithrom­bot­ic or throm­bolyt­ic med­ica­tions while tak­ing ADUHELM may in­crease the risk of bleed­ing in the brain.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER